Orrick has advised Paris-based Inato, a platform that helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials, on its $14 million Series A financing round. The financing was led by Obvious Ventures and Cathay Innovation, with participation from previous investors Serena and Fly Ventures. As a part of the financing, Nan Li, managing director at Obvious Ventures, has joined Inato’s board of directors.
The Orrick team advising Inato includes Ben Cichostepski
, Rena Kakon
and Vincent Babin